Opus Genetics Inc (NASDAQ:IRD)’s traded shares stood at 0.38 million during the last session, with the company’s beta value hitting 0.18. At the close of trading, the stock’s price was $1.18, to imply an increase of 9.26% or $0.1 in intraday trading. The IRD share’s 52-week high remains $3.40, putting it -188.14% down since that peak but still an impressive 31.36% since price per share fell to its 52-week low of $0.81. The company has a valuation of $37.25M, with an average of 0.38 million shares in intraday trading volume over the past 10 days and average of 198.95K shares over the past 3 months.
Opus Genetics Inc (NASDAQ:IRD) trade information
After registering a 9.26% upside in the last session, Opus Genetics Inc (IRD) has traded red over the past five days. The 5-day price performance for the stock is 19.54%, and 8.26% over 30 days. With these gigs, the year-to-date price performance is -60.80%. Short interest in Opus Genetics Inc (NASDAQ:IRD) saw shorts transact 0.88 million shares and set a 4.69 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Opus Genetics Inc (IRD) estimates and forecasts
Looking at statistics comparing Opus Genetics Inc share performance against respective industry, we note that the company has underperformed competitors. Opus Genetics Inc (IRD) shares are -22.88% down over the last 6 months, with its year-to-date growth rate lower than industry average at -165.22% against 16.60%. The rating firms project that company’s revenue will shrink -6.57% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 11.1M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 2M.Earnings reports from the last fiscal year show that sales brought in 1.69M and 1.71M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 556.67% before jumping 16.89% in the following quarter.
IRD Dividends
Opus Genetics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Opus Genetics Inc (IRD) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 675.82 shares. This is just over 2.14% of the total shares, with a market valuation of $0.8 million. Data from the same date shows that the other fund manager holds a little less at 288.95, or 0.92% of the shares, all valued at about 0.34 million.
